Serum albumin predicts hyperuricemia in patients with idiopathic membranous nephropathy

Cuimei Wei
The First Affiliated Hospital of Shenzhen University

Tong Li
The First Affiliated Hospital of Shenzhen University

Xuan Xuan
The First Affiliated Hospital of Shenzhen University

Xiaohua Xiao (✉ 13622308340@163.com)
The First Affiliated Hospital of Shenzhen University

Junyi Li
The First Affiliated Hospital of Shenzhen University

Research Article

Keywords: serum albumin, hyperuricemia, uric acid, cross-sectional study, idiopathic membranous nephropathy

DOI: https://doi.org/10.21203/rs.3.rs-199182/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Aim:** The aim of the study was to examine the cross-sectional association between serum albumin and hyperuricemia (HU).

**Subjects and methods:** HU was defined as uric acid ≥420 mol/L for the male population and ≥357 mol/L for the female population. We reviewed the files of 216 consecutive patients with idiopathic membranous nephropathy treated at our hospital between 2010 and 2019. The correlation of serum albumin with hyperuricemia and the association between serum uric acid levels and the clinical of idiopathic membranous nephropathy were assessed by statistical analysis. A multivariable logistic analysis model was applied to test the association after adjusting for a number of potential confounding factors.

**Results:** Triglyceride and serum albumin were higher in group with hyperuricemia than in group without hyperuricemia (p=0.020, P=0.001 respectively). As serum albumin rose for 1 g/L, the probability for hyperuricemia increased for 17% (adjusted II OR= 1.17, 95%CI (1.02, 1.35), P = 0.0294). A unit increase in serum albumin was associated with increases of 6.64 umol/L in uric acid (adjusted II β = 6.64, P = 0.0135). Using Tertile 1 (T1) for reference, Tertile 3 (T3) group was positively associated with both hyperuricemia (adjusted II OR=44.21, 95%CI(12.76, 75.67), P=0.0064) and uric acid (adjusted II β=98.64, P=0.0116). The interaction test showed significant interactions between serum albumin and hyperuricemia and had a higher β between serum albumin and uric acid than BMI 25 kg/m² (for hyperuricemia: OR = 1.01 vs 1.18, P for interaction = 0.0056; for uric acid: β = 0.96 vs 6.23, P for interaction = 0.0154). The area under the ROC curve (AUC) was 0.7615 in the participants BMI ≥25 kg/m². The sensitivity and specificity of this point were 47.37% and 95.83%, respectively.

**Conclusion:** Our study showed that serum albumin was positively associated with hyperuricemia and uric acid, especially in obese subjects.

Introduction

Membranous nephropathy (MN) refers to a group of diseases characterized by the deposition of immune complexes in the epithelial cells of the glomerular basement membrane (GBM), accompanied by GBM thickening. Unexplained is called idiopathic membranous nephropathy (IMN). IMN is a common pathological type of nephrotic syndrome in adults\[^1\] and accounted for 70-80% of all membranous nephropathy (MN) patients. Recent studies have shown that the epidemiological characteristics of MN recent years significant changes have taken place, MN accounting primary glomerular diseases (PGD) of 23.4% \[^2\]. The clinical features and prognosis of IMN are variable, ranging from spontaneous remission of nephrotic syndrome (up to 20-60%) to a slow, progressive decline in glomerular filtration rate over several years. However, approximately 20% of IMN patients develop end-stage renal disease or die from related complications within 5 to 15 years. Recent epidemiological studies have shown that associated with hypertension and hyperuricemia IgAN patients with metabolic syndrome is an important risk factor for chronic kidney disease progression\[^3\-6\]. However, most controlled clinical studies have focused on determining the relationship between high blood pressure, hyperglycemia and kidney disease, few studies have examined the clinical and prognostic significance of serum uric acid in membranous nephropathy. It is reported that uric acid levels may predict renal function in individuals with normal renal function insufficiency of development and is associated with the onset of proteinuria and renal function in patients with type II diabetes mellitus\[^7\]. Several observational studies examined the uric acid is an independent risk factor for chronic kidney disease (CKD) and progression\[^8\-9\]. We hypothesize that the serum uric acid is associated with initial worsening of IMN and plays a role in disease progression in IMN. Therefore, the goal of this study was to examine the association between serum albumin and hyperuricemia in a cohort of patients with idiopathic membranous nephropathy.

Materials And Methods

**Study Population.** A total of 236 patients with biopsy proven membranous nephropathy (MN), treated at the First Affiliated Hospital of Shenzhen University from January 1, 2010 to December 12, 2019 were evaluated for inclusion in this retrospective analysis, of whom 6 were excluded for atypical membranous nephropathy. Of the remaining 230 patients, patients with secondary MN (n = 14) were excluded. Finally, a total of 216 patients (124 males: 57.41%, mean age: 44.83 ± 15.03 years) with previously diagnosed IMN were included in the study. This study was reviewed and approved by the Ethics Committee of First Affiliated Hospital of Shenzhen University and was conducted in accordance with the guidelines of the Declaration of Helsinki. Written informed consent was obtained from each patient.

**Clinical Parameters.** Baseline data at the time of renal biopsy were obtained from medical records and included age, sex, the presence of hypertension (HTN), and eGFR. Laboratory data for serum creatinine, albumin, estimated glomerular filtration rate (eGFR), and the spot urine protein-to-creatinine ratio (UPCR) were obtained in the morning after admission under fasting conditions. The weight and height of each subject were measured, respectively, to calculate the body mass index (BMI). The smoking and alcohol drinking status were asked face to face. Blood pressure was measured by an electronic sphygmomanometer. Subjects with the systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or who were currently undergoing drug treatment for blood pressure control were regarded as hypertension patients. The estimated glomerular filtration rate (eGFR) was calculated using the Modification in Diet and Renal Disease (MDRD) equation\[^10\]. eGFR [ml/min/1.73 m²] = 175 × [serum creatinine] -1.234 × [age] -0.197 × [female] × 0.79.

**Study Group Design.** Patients were divided into groups with or without hyperuricemia depending on their serum uric acid levels at the time of renal biopsy.

**Statistical Analysis.** The χ² test for categorical variables and the Kruskal-Wallis or Mann-Whitney test for continuous variables were used to compare univariate predictors of clinical outcomes between the two groups. Differences between groups using an independent t-test for continuous variables assessed, and the Kruskal-Wallis test for categorical variables, frequencies, and percentages. Logistic regression analysis was used to elucidate the association between hyperuricemia and other clinic parameters. The dependent variable was serum uric acid levels coded as 0 for IMN without hyperuricemia and coded as 1 for IMN with hyperuricemia. Interaction and stratified analyses were conducted according to age (<45 and ≥45 years), sex (male and female), smoking status (never smoked and smokers), drinking status (non-drinker and drinkers), histories of chronic diseases and some...
may explain the relationship between elevated serum albumin levels and the risk of metabolic syndrome or hyperuricemia.

over-nutrition, such as obesity and metabolic syndrome, a high serum albumin level has been related to parameters indicative of nutritional status as a nutritional marker. Serum albumin levels may be affected by the nutritional status.

Serum albumin and the above covariates, except for BMI (Table 4). Obese subjects are more important than the relationship between non-obese subjects. The interaction test showed that when using hyperuricemia or uric acid to determine the results, there was no significant interaction between serum albumin and the above covariates, except for BMI. The participants BMI ≥25 kg/m² had a higher OR between serum albumin and hyperuricemia and had a higher β between serum albumin and uric acid (for hyperuricemia: OR = 1.01 vs 1.18, P for interaction = 0.0056; for uric acid: β = 0.96 vs 6.23, P for interaction = 0.0154).

In addition, smooth curve fitting was performed after the adjustment of the variables. We found a linear association of serum albumin and hyperuricemia. That is, serum albumin is positively correlated with hyperuricemia figure1.

In our study, ROC analysis was used to seek for the panel of parameters that might display the best specificity and sensitivity for discrimination of patients with hyperuricemia from those who did not have it. According to BMI, the patients were divided into two groups (<25 kg/m² vs ≥25 kg/m²), the area under the ROC curve (AUC) was larger in obese subjects than in non-obese subjects. The area under the ROC curve (AUC) was 0.762 in the participants BMI ≥25 kg/m². The sensitivity and specificity of this point were 47.37% and 95.83%, respectively figure2.

**Discussion**

Chronic kidney disease (CKD) is a public health problem with many risk factors and its progression is hard to control. Thus it is more important to prevent the occurrence of this disease rather than to manage it. Hyperuricemia was reported to be a risk factor for CKD. Cirillo et al. previously found that serum uric acid plays an important role in the progression of CKD. In our cross-sectional study, which was conducted to assess the clinical data of patients with different serum uric acid levels, we found there are significant differences in clinical and laboratory tests between patients with and without hyperuricemia groups. Hyperuricemia is often associated with chronic renal tubulointerstitial disease, which can lead to renal interstitial fibrosis at a later stage. Renal ischemia, renal arteriosclerosis, and glomerulosclerosis can develop as a result of compressed blood vessels. In this study, multivariate logistic regression analysis showed that serum albumin kept independent prediction on hyperuricemia.

Uric acid is the metabolic end product of purine metabolism in humans. In accordance with some reports, hyperuricemia induces endothelial dysfunction and low inflammation by inhibiting the production of nitric oxide and the production of reactive oxygen species. According to some researchs, there was a significant positive correlation between uric acid concentration and hs-CRP level, while serum albumin level was negatively correlated with hs-CRP. Serum albumin levels may be affected by the nutritional status as a nutritional marker. High serum albumin level has been related to parameters indicative of over-nutrition, such as obesity and metabolic syndrome. Elevated serum albumin levels may reflect excessive nutritional status in the body, which may explain the relationship between elevated serum albumin levels and the risk of metabolic syndrome or hyperuricemia. However, in the case of
chronic inflammation associated with hyperuricemia, albumin levels may be reduced by inflammation even in hypertrophic conditions, which may reduce the role of albumin as an indicator of overnutrition and serve as a marker for predicting incident metabolic syndrome[21].

We found few studies on hyperuricemia incidence risk among idiopathic membranous nephropathy patients. To elucidate the impact of serum albumin on hyperuricemia in idiopathic membranous nephropathy patients, we estimated the association between serum albumin and the risk of hyperuricemia in both men and women. Our results suggest that elevated serum albumin is independently and positively associated with an increased risk of hyperuricemia in people, especially in the participants BMI $\geq 25$ kg/m$^2$. This cross-sectional study observed a significant association between the serum albumin level and the prevalence of hyperuricemia, independent of some major confounding factors. We find that triglyceride and serum albumin were higher in group with hyperuricemia than in group without hyperuricemia. Similarly serum uric acid was significantly positively correlated with serum albumin, triglyceride and body mass index (BMI).

You-Bin Lee et al. [21] indicated that higher levels of albumin were associated with an increased risk of incident MetS only in individuals with lower uric acid whereas higher levels of uric acid were positively linked to risk of incident MetS regardless of albumin level. This study presented further evidence that hyperproteinemia plays a key role in the pathogenesis of HU. The participants BMI $\geq 25$ kg/m$^2$ had a higher OR between serum albumin and hyperuricemia and had a higher $\beta$ between serum albumin and uric acid.

The limitations of our study are cross-sectional design and small sample size. However, the present study has the strength. This is one of a few studies examined the association between serum albumin and the prevalence of hypeluricemia by regarding serum albumin as the primary exposure. In one cross-sectional study indicated that the increased value of baseline serum albumin was positively associated with metabolic syndrome (MetS) prevalence or incidence[23].

Conclusion

In conclusion, as serum uric acid is a common and easily available measurement in clinical activity, it is a convenient and feasible way to identify those patients who are at high risk of developing end stage renal disease (ESRD) and with poor prognosis. We found that serum albumin levels are positively associated with hyperuricemia and uric acid especially patients with idiopathic membranous nephropathy, especially in obese subjects, which provide potential evidence that serum albumin may play an important role in regulating uric acid and hyperuricemia. Large prospective studies and independent replications are required to elucidate these issues.

Declarations

Acknowledgement

This research was supported by the First Affiliated Hospital of Shenzhen University.

Author contributions

Author contributions WCM, XX, LT and XH X contributed in the conception of the work, conducting the study, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. WCM and LJY contributed in the conception of the work, drafting and revising the draft. All authors read and approved the final version of the manuscript.

Funding

This study was supported in part by the basic research project and technology development projects of Shenzhen Municipal Science and Technology Innovation Council accounts JCY20180507184647636. All aspects of manuscript writing and revision were carried out by the coauthors.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available to protect the identification of the participants but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was reviewed and approved by the Ethics Committee of First Affiliated Hospital of Shenzhen University and was conducted in accordance with the guidelines of the Declaration of Helsinki. All patients were informed that their anonymized personal data could be used for research. Written informed consent was obtained from each patient.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Geriatrics, The First Affiliated Hospital of Shenzhen University, No. 3002 Sungang Road, Futian, Shenzhen 518035, Guangdong, China
References

[1] Jan A.J.G. van den Brand, Hofstra, et al. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. *Clin J Am Soc. Nephrol.* 2011;6(12):2846-2853.

[2] Xin Xu, Guobao Wang, Fan Fan Hou, et al. Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China. *J Am Soc Nephrol.* 2016;27(12):3739-746.

[3] Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, Atkins RC. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. *J Am Soc Nephrol.* 2003;14( Suppl 2): S131-S138.

[4] Romundstad S, Holmen J, Hallan H, Kvenild K, Krüger O, Midthjell K. Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population. The Nord-Trendelag Health Study (HUNT, 1995-97), Norway. *J Intern Med.* 2002; 252 (2): 164-172.

[5] Iseki K, Kohagura K, Sakima A, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). *Hypertens Res.* 2007; 30 (1): 55-62.

[6] Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. *J Am Soc Nephrol.* 2005; 16 (2): 529-538.

[7] Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. *Diabetes Care.* 2012; 35 (1): 99-104.

[8] Bellomo G, Venanzi S, Verdua C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. *Am J Kidney Dis.* 2010; 56 (2): 264-272.

[9] Rosolowsky ET, Piccioletto LH, Maselli NJ, Niewczas MA, Binns AL, Roshan B, Warram JH, Krolewski AS. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonprotienuric patients with type 1 diabetes. *Clin J Am Soc Nephrol.* 2008; 3 (3): 706-713.

[10] Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Laneire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes(KDIGO). *Kidney Int.* 2005; 67 (6): 2089-2100.

[11] Cirillo P, Sato W, Reungjui S, Heinig M, Gersch M, Sautin Y, Nakagawa T, Johnson RJ. Uric acid, the metabolic syndrome, and renal disease. *J Am Soc Nephrol.* 2006; 17 (12 Suppl 3): S165-S168.

[12] Barberi S, Menè P. Role of uric acid in hypertension and in the progression of chronic renal disease. *G Ital Nefrol.* 2006; 23(1): 4-11.

[13] So A, Thorens B: Uric acid transport and disease. *Clin Invest* 2010;120(6):1791–1799.

[14] Yu TY, Jee JH, Baec JH, Lee MK, Kim JH. Serum uric acid: a strong and independent predictor of metabolic syndrome after adjusting for body composition. *Metabolism.* 2016;65(4):432-40.

[15] Khosla UM, Zharikov S, Finch JL, Nakagawa T, et al. Hyperuricemia induces endothelial dysfunction. *Kidney Int* 2005;67(5):1739-42.

[16] Krajcoviechova A, Tremblay J, Wohlfahrt P, Bruthans J, Tahir MR, Hamet P, Cifkova R. The impact of blood pressure and visceral adiposity on the association of serum uric acid with albuminuria in adults without full metabolic syndrome. *Am J Hypertens.* 2016;29(12):1335-42.

[17] Ishizaka N, Ishizaka Y, Nagai R, Toda E, Hashimoto H, Yamakado M. Association between serum albumin, carotid atherosclerosis, and metabolic syndrome in Japanese individuals. *Atherosclerosis.* 2007;193(2):373-9.

[18] Kadono M, Hasegawa G, Shigeta M, Nakazawa A, Ueda M, Yamazaki M, Fukui M, Nakamura N. Serum albumin levels predict vascular dysfunction with paradoxical pathogenesis in healthy individuals. *Atherosclerosis.* 2010;209(1):266-70.

[19] Jin SM, Hong YJ, Jee JH, Bae JC, Hur KY, Lee MK, Kim JH. Change in serum albumin concentration is inversely and independently associated with risk of incident metabolic syndrome. *Metabolism.* 2016;65(11):1629-35.

[20] Saito I, Yonematsu K, Inami F. Association of body mass index, body fat, and weight gain with inflammation markers among rural residents in Japan. *Circ J.* 2003;67(4):323-9.
You-Bin Lee, Ji Eun Jun, Seung-Eun Lee et al. Utility of Serum Albumin for Predicting Incident Metabolic Syndrome according to Hyperuricemia. Diabetes Metab J. 2018;42(6):529-537.

Tuo Yang, Xiang Ding, Yi-lun Wang et al. Association between high sensitivity C reactive protein and hyperuricemia. Rheumatol Int. 2016;36(4):561–566.

Jin SM, Hong YJ, Jee JH, Bae JC, Hur KY, Lee MK, Kim JH. Change in serum albumin concentration is inversely and independently associated with risk of incident metabolic syndrome. Metabolism. 2016;65(11):1629-35.

### Table 1: Demographic, clinical, and laboratory features of IMN patients with and without Hyperuricemia

|                          | IMN without Hyperuricemia | IMN with Hyperuricemia | P value |
|--------------------------|---------------------------|------------------------|---------|
| n (male/female)          | 116/58/58                 | 100/68/34              | 0.018   |
| Age (year)               | 43.54 ± 14.75             | 46.33 ± 15.29          | 0.175   |
| Alcohol (n/%)            | 8 (6.9%)                  | 8 (8.00%)              | 0.757   |
| Smoke (n/%)              | 12 (10.34%)               | 18 (18%)               | 0.105   |
| Hypertension (n/%)       | 47 (40.52%)               | 53 (53%)               | 0.067   |
| AKI (n/%)                | 4 (3.45%)                 | 11 (11%)               | 0.029   |
| BMI (kg/m²)              | 23.72 ± 3.12              | 25.11 ± 4.45           | 0.027   |
| Systolic pressure (mmHg) | 133.11 ± 19.46            | 135.49 ± 20.94         | 0.388   |
| Diastolic pressure (mmHg)| 80.96 ± 11.68             | 82.77 ± 12.60          | 0.274   |
| 24-hour urinary protein (mg/dl) | 3648.85 (2253.25-5928.30) | 3267.45 (1716.40-5464.80) | 0.197 |
| HGB (g/L)                | 129.97 ± 18.04            | 134.23 ± 20.27         | 0.103   |
| GLU (mmol/L)             | 5.01 ± 1.32               | 4.84 ± 0.82            | 0.266   |
| HbA1c (%)                | 5.86 ± 1.84               | 5.65 ± 0.84            | 0.425   |
| Serum albumin (g/L)      | 25.10 ± 6.50              | 28.30 ± 7.51           | <0.001  |
| Uric acid (mmol/L)       | 319.50 ± 50.95            | 469.58 ± 74.39         | <0.001  |
| eGFR (ml/min)            | 116.55 ± 35.19            | 102.31 ± 30.43         | 0.002   |
| Total cholesterol (mmol/L)| 7.49 ± 2.29               | 6.96 ± 2.14            | 0.044   |
| Triglyceride (mmol/L)    | 1.67 (1.19-2.69)          | 2.11 (1.50-3.05)       | 0.020   |
| High density lipoprotein (mmol/L) | 1.53 (1.19-1.82)       | 1.23 (1.06-1.54)       | 0.006   |
| Low density lipoprotein (mmol/L) | 4.82 ± 1.93                | 4.53 ± 1.87            | 0.276   |
| ALT (U/L)                | 15.50 (11.00-23.00)       | 14.35 (11.00-19.15)    | 0.695   |

Data are mean±SD or median (25th to 75th percentile).

Abbreviations: AKI, Acute kidney injury; BMI, body mass index; eGFR, estimated glomerular filtration rate; HGB, Hemoglobin; GLU, glucose; Glycated hemoglobin, HbA1c; ALT, alanine aminotransferase.

Table 2: Spearman’s correlation analysis between serum uric acid and clinical parameters in patients with IMN.
| Predictors                        | Rho (ρ) | P value  |
|----------------------------------|---------|----------|
| Age (year)                       | 0.0338  | 0.6215   |
| Serum albumin (g/L)              | 0.2345  | 0.0005   |
| eGFR (ml/min)                    | -0.2802 | 0.0000   |
| 24-hour urinary protein (g/d)    | -0.0868 | 0.2159   |
| FPG (mmol/L)                     | 0.2503  | 0.0002   |
| Total cholesterol (mmol/L)       | -0.1524 | 0.0525   |
| High density lipoprotein (mmol/L)| -0.1985 | 0.0035   |
| Low density lipoprotein (mmol/L) | -0.0970 | 0.1565   |
| ALT (U/L)                        | 0.0674  | 0.3300   |
| GLU (mmol/L)                     | -0.0116 | 0.8101   |
| TC (mmol/L)                      | -0.0674 | 0.3300   |
| HDL (mmol/L)                     | 0.0674  | 0.3300   |
| LDL (mmol/L)                     | 0.0674  | 0.3300   |
| ALT (U/L)                        | 0.0674  | 0.3300   |
| GLU (mmol/L)                     | 0.0674  | 0.3300   |
| Table 3. Univariate and multivariate regression for effects of serum albumin on uric acid and hyperuricemia |

| hyperuricemia | Crude OR,95%CI | P value | Adjust I OR,95%CI | P value | Adjust II OR,95%CI | P value |
|---------------|---------------|---------|----------------|---------|----------------|---------|
| Crude         | 1.07 (1.03, 1.11) | 0.0013 | 1.09 (1.04, 1.17) | 0.0006 | 1.17 (1.02, 1.35) | 0.0294 |
| Adjust I      | 2.17 (0.73, 2.76) | 0.3087 | 2.17 (0.75, 4.32) | 0.1875 | 2.70 (0.10, 7.40) | 0.8741 |
| Adjust II     | 2.17 (0.73, 2.76) | 0.3087 | 2.17 (0.75, 4.32) | 0.1875 | 2.70 (0.10, 7.40) | 0.8741 |

| uric acid | Crude OR,95%CI | P value | Adjust I OR,95%CI | P value | Adjust II OR,95%CI | P value |
|-----------|---------------|---------|----------------|---------|----------------|---------|
| Crude     | 0.0294 (1.43, 5.99) | 0.0005 | 0.0294 (1.43, 5.99) | 0.0005 | 0.0294 (1.43, 5.99) | 0.0005 |
| Adjust I  | 0.0294 (1.43, 5.99) | 0.0005 | 0.0294 (1.43, 5.99) | 0.0005 | 0.0294 (1.43, 5.99) | 0.0005 |
| Adjust II | 0.0294 (1.43, 5.99) | 0.0005 | 0.0294 (1.43, 5.99) | 0.0005 | 0.0294 (1.43, 5.99) | 0.0005 |

Non-adjusted model adjust for: None
Adjusted I: age, sex, body mass index, smoking status, drinking status, hypertension, eGFR, AKI, HBP
Adjusted II: age, sex, body mass index, smoking status, drinking status, triglyceride, 24-hour urinary protein, eGFR, AKI, HGB

Table 4. Stratified and interaction analysis for effects of serum albumin on uric acid and hyperuricemia
|                   | OR, 95% CI | P Value | P interaction | OR, 95% CI | P Value | P interaction |
|-------------------|------------|---------|---------------|------------|---------|---------------|
| **Years old**     |            |         |               |            |         |               |
| 110               | 1.09 (1.03,1.15) | 0.0025 | 0.3752        | 3.82 (1.35, 6.29) | 0.0031 |               |
| 106               | 1.05 (0.98,1.11) | 0.1542 | 2.23 (0.38,4.84) | 0.0969 |         |               |
| **Sex**           |            |         |               |            |         |               |
| Male              | 1.10 (1.02,1.18) | 0.0099 | 0.518         | 4.31 (1.82, 6.81) | 0.0011 | 0.7218        |
| Female            | 1.07 (1.02,1.13) | 0.0114 | 3.70 (1.51, 5.88) | 0.0012 |         |               |
| **Smoking habits**|            |         |               |            |         |               |
| Yes               | 1.07 (1.02,1.12) | 0.0034 | 3.50 (1.57, 5.42) | 0.0005 |         |               |
| No                | 1.09 (0.97,1.22) | 0.1620 | 1.79 (-2.47,6.05) | 0.4179 |         |               |
| **Hypertension**  |            |         |               |            |         |               |
| Yes               | 1.07 (1.02,1.11) | 0.0025 | 3.32 (1.43, 5.20) | 0.0007 |         | 0.7187        |
| No                | 1.10 (0.93,1.29) | 0.2608 | 2.10 (-2.81,7.01) | 0.4165 |         |               |
| **Diabetes**      |            |         |               |            |         |               |
| Yes               | 1.09 (1.02,1.16) | 0.0070 | 0.4507        | 5.43 (2.60, 8.25) | 0.0003 | 0.0271        |
| No                | 1.06 (1.00,1.12) | 0.0461 | 1.48 (-0.69,3.65) | 0.1851 |         |               |
| **Kidney insufficiency** | | | | | | |
| Yes               | 1.09 (1.04,1.15) | 0.0008 | 3.24 (1.18, 5.31) | 0.0025 |         |               |
| No                | 1.04 (0.97,1.12) | 0.2557 | 0.3262        | 4.28 (1.01, 7.55) | 0.0127 | 0.5904        |
| **Hyperuricemia** |            |         |               |            |         |               |
| Yes               | 1.12 (1.04,1.20) | 0.0015 | 4.65 (1.91, 7.40) | 0.0012 |         |               |
| No                | 1.08 (0.99,1.17) | 0.0869 | 0.4846        | 4.59 (0.75, 8.43) | 0.0212 | 0.9789        |
| **HGB**           |            |         |               |            |         |               |
| Yes               | 1.07 (0.98,1.18) | 0.1335 | 2.45 (-0.83,5.73) | 0.1492 |         |               |
| No                | 1.06 (1.02,1.11) | 0.0090 | 0.8573        | 2.78 (0.65, 4.92) | 0.0115 | 0.8802        |
| **Triglyceride**  |            |         |               |            |         |               |
| <1.7              | 1.05 (0.98,1.11) | 0.1553 | 2.02 (-0.20,4.24) | 0.0783 |         |               |
| >=1.7             | 1.10 (1.04,1.17) | 0.0011 | 0.2501        | 4.49 (2.00, 6.98) | 0.0006 | 0.1615        |
| **Total cholesterol**|        |         |               |            |         |               |
| <5.2              | 1.11 (0.96,1.29) | 0.1424 | 4.84 (-0.11,9.78) | 0.0626 |         | 0.5858        |
| >=5.2             | 1.06 (1.01,1.11) | 0.0113 | 0.5395        | 3.08 (0.86, 5.31) | 0.0073 |         |               |
| **BMI**           |            |         |               |            |         |               |
| <25               | 1.01 (0.95,1.08) | 0.6488 | 0.96 (-1.62,3.53) | 0.4688 |         |               |
| >=25              | 1.18 (1.07,1.31) | 0.0056 | 6.23 (2.64, 9.82) | 0.0012 |         | 0.0154        |

**Figures**
Figure 1
Smooth curve fitting of serum albumin and hyperuricemia. Adjustment variables: age, sex, body mass index, smoking status, drinking status, hypertension, AKI, HGB; TG; eGFR; 24-hour urinary protein.

Figure 2
ROC curve of the relationship between serum albumin and hyperuricemia in BMI ≥ 25 kg/m².